Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Moderate to Severe Conjunctivochalasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02804191
Recruitment Status : Unknown
Verified September 2017 by Ocuwize LTD.
Recruitment status was:  Recruiting
First Posted : June 17, 2016
Last Update Posted : September 26, 2017
Sponsor:
Information provided by (Responsible Party):
Ocuwize LTD

Brief Summary:
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients with Moderate to Severe Conjunctivochalasis

Condition or disease Intervention/treatment Phase
Conjunctivochalasis Drug: LO2A Drug: Saline Phase 2

Detailed Description:

Phase 2, randomized, placebo-controlled, parallel group, study in up to 62 adult patients with moderate to severe CCh. Eligible patients will be randomly assigned in a 1:1 ratio to one of two treatment groups, LO2A or placebo, stratified by LIPCOF grade at baseline.

This study with 4 visits, will consist of a screening period of up to 2 weeks and a 3-month treatment period (topical, OU, QID application of eye drops).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Moderate to Severe Conjunctivochalasis
Actual Study Start Date : July 2016
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : June 2018

Arm Intervention/treatment
Experimental: LO2A
Sodium Hyaluronate
Drug: LO2A
eye drop solution.

Placebo Comparator: Placebo-Controlled
Saline.
Drug: Saline
Placebo




Primary Outcome Measures :
  1. The change from baseline in lissamine green conjunctival staining (LGCS) score. [ Time Frame: 3 Months ]

Secondary Outcome Measures :
  1. The change in the lid-parallel conjunctival fold (LIPCOF) grade score at 1 and 3 months compared to baseline [ Time Frame: 3 Months ]
  2. The change from baseline in LGCS score [ Time Frame: 1 month ]
  3. The change in tear-film break up time (TFBUT) compared to baseline at 1 and 3 months [ Time Frame: 3 Months ]
  4. The change in ocular surface disease index (OSDI) questionnaire score compared to baseline at 1 and 3 months [ Time Frame: 3 Months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female of any race and ≥ 18 years of age.
  2. Willing and able to provide voluntary written informed consent.
  3. Moderate to severe conjunctivochalasis defined by:

    • LIPCOF score ≥ 2; and
    • Lissamine green conjunctival staining score ≥ 5 according to National Eye Institute/Industry Workshop report.
  4. Willing and able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

  1. Subject has concurrent, uncontrolled medical condition, or psychiatric illness which could place him/her at unacceptable risk, including, but not limited to:

    • Subject has been diagnosed or treated for another malignancy within 3 years of screening, except in situ malignancy, or low-risk prostate, skin or cervix cancer after curative therapy.
    • A co-morbid condition which, in the view of the Investigators, renders the subject at high risk from treatment complications.
  2. Subjects with pterygium.
  3. Subjects with active, allergic keratoconjunctivitis, or conjunctivitis of infectious origin.
  4. Subjects with blepharitis requiring treatment.
  5. Subjects with a history of surgery affecting the eye surface, as well as eye injuries within 3 months of screening.
  6. Subjects currently using any topical ophthalmic treatment (including medications for glaucoma) or over-the-counter (OTC) solutions, artificial tears, gels or scrubs, and cannot discontinue these medications for the duration of the trial.
  7. Subjects who have used any of the following medications or treatments:

    • LASIK or PRK surgery within 12 months of Visit 1.
    • Use of contact lenses within 7 days of Visit 1.
    • Punctal plug insertion within 30 days of Visit 1.
    • Use of topical or systemic cyclosporine within 30 days of Visit 1.
    • Use of medications known to cause ocular drying (e.g. antihistamines, sleep aids, etc.), unless at a stable dose, within 30 days of Visit 1.
  8. Known hypersensitivity to sodium hyaluronate or any LO2A excipients (glycerol and Carbomer 981).
  9. Active abuse of alcohol or drugs.
  10. Any condition, which in the opinion of the Investigator, would place the patient at an unacceptable risk if participating in the study protocol.
  11. Participation in a clinical trial of an investigational (unapproved) drug or device within 1 month prior to screening or scheduled to receive another investigational drug or device during this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02804191


Contacts
Layout table for location contacts
Contact: Adam Foley-Comer, MD 054 749 1753 ext +972 adam@wizepharma.com

Locations
Layout table for location information
Israel
Rambam Recruiting
Haifa, Israel
Contact: Sergeu Socae, M.D       sergiusoc@gmail.com   
Contact: Meital       m_abecassis@rambam.health.gov.il   
Hadassah Recruiting
Jerusalem, Israel
Contact: Avi Solomon, M.D       dr.avi.solomon@gmail.com   
Ichilov Tel Aviv hospital Recruiting
Tel Aviv, Israel
Contact: David Varssano, M.D    972-5242663000    'varssano@gmail.com'   
Contact: Keren Elia Ogalbo    972-36974165      
Sponsors and Collaborators
Ocuwize LTD
Investigators
Layout table for investigator information
Study Director: Or Eisenberg, CPA Ocuwize Pharma

Layout table for additonal information
Responsible Party: Ocuwize LTD
ClinicalTrials.gov Identifier: NCT02804191     History of Changes
Other Study ID Numbers: WP-LO2A-01
First Posted: June 17, 2016    Key Record Dates
Last Update Posted: September 26, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Final Data report will be publish when the study will be finalized
Additional relevant MeSH terms:
Layout table for MeSH terms
Ophthalmic Solutions
Pharmaceutical Solutions